Elanco

The FDA approved multiple animal drugs from August to November, including Zenrelia for atopic dermatitis in dogs, Credelio Quattro for antiparasitic treatment, and Coxidin 90 for poultry. Supplemental approvals for antiparasitic drugs now include protection against Asian longhorned ticks. The first generic monensin Type A medicated article for chickens, turkeys, and quail was also approved.

Elanco Animal Health advances livestock sustainability with FDA approvals for Experior and MGA combinations in heifers, reducing ammonia emissions by up to 16%. These innovations offer flexibility to producers, aligning environmental stewardship with economic sustainability. Elanco also highlights Rumensin's role in decreasing methane emissions, contributing to significant GHG reductions. The company advocates for livestock as part of climate solutions, engaging in global forums like COP29 and influencing consumer perceptions on sustainability.

Pharmaust rebrands as Neurizon Therapeutics, focusing on neuro-degenerative diseases like ALS, using repurposed animal drug monepantel. The company plans a pivotal phase II/III trial with FDA fast-track approval potential, supported by a $900,000 grant from Fight MND.

The Global Animal Biotechnology Market 2024 report by Coherent Market Insights details market dynamics, value chain, investment hotspots, competitive scenarios, and regional landscapes. Key players include Heska Corporation, Indian Immunologicals Ltd., and HESTER BIOSCIENCES LIMITED. The report offers insights into market segmentation, financial analysis, and strategic decision-making, aiding stakeholders in gaining a competitive edge.

An Elanco investor filed a securities class action alleging the company misled investors about the safety of a canine dermatitis treatment and drug launch timelines.

We've detected unusual activity from your computer network. To continue, click the box below to confirm you're not a robot.

FDA approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitis. Elanco enters the $1.7 billion global canine dermatology market. Zenrelia is at least as effective as the market incumbent JAK inhibitor, with 77% of dogs achieving clinical remission of itch compared to 53% with Apoquel. Zenrelia launch begins in the U.S., with orders now being taken and expected to ship soon.

The FDA approved ilunocitinib tablets (Zenrelia; Elanco) for pruritus and atopic dermatitis in dogs. This JAK inhibitor is administered orally once daily and is the second of its kind approved by the FDA. Elanco conducted a study comparing ilunocitinib to oclacitinib, showing noninferiority. The drug is available in various strengths and requires a prescription.